C-FDMWLoyal
canine aging therapeutics, metabolic dysfunction
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-FDMW
C-FDMWC-FDMWcanine aging therapeutics, metabolic dysfunction
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Celine Halioua built Loyal to give dogs more healthy years with the people who love them. Watch the full Outlier Briefing on our channel now.
Can you extend a dog's lifespan? Loyal founder and CEO Celine Halioua is running the first ever FDA-concurred lifespan extension clinical trial to find out. In this episode of Outlier Briefings, Bain Capital Ventures partner Kevin Zhang sits down with Celine to talk about building Loyal from the ground up, navigating a regulatory path that had never existed before and what the Stay Study, a 1,300-dog clinical trial across 70 veterinary clinics in the US, could mean for the future of aging, for dogs and humans alike. Watch and learn more about dog longevity science and why dogs are the best model for human aging, how Celine is building the first FDA regulatory path for a lifespan extension drug, the Stay Study (the largest canine lifespan clinical trial ever conducted) and what it takes to go from contrarian to consensus as a biotech founder. 0:00 Introduction 0:25 What is Loyal? 1:03 Why dogs are the best model for human aging 2:13 Going from "laughed at" to running a clinical trial 2
What if the biggest barrier to a longer life isn't science, but the economic incentives of corporations? In this episode of Onward, Ben sits down with Celine Halioua, founder and CEO of Loyal — the biotech company on track to earn the first-ever FDA approval for a drug whose only purpose is to extend lifespan. The catch: they're starting with dogs. Celine walks Ben through why the U.S. healthcare system is structurally incapable of building preventative medicine, why each dog-owner relationship is a "micro single-payer health care system," and how a quiet 2019 change to FDA regulation was the one-to-one cause of Loyal existing at all. ("If this pathway didn't exist, Loyal wouldn't exist. October 2019, I incorporated.") From there, the conversation widens. Celine lays out the Tesla-style master plan — save the dogs, save the world — that uses dog-drug revenue to fund human longevity work, escaping the discipline of biotech VC entirely. Ben presses her on AI in drug development (she'
What if the biggest barrier to a longer life isn't science, but the economic incentives of corporations? In this episode of Onward, Ben sits down with Celine Halioua, founder and CEO of Loyal — the biotech company on track to earn the first-ever FDA approval for a drug whose only purpose is to extend lifespan. The catch: they're starting with dogs. Celine walks Ben through why the U.S. healthcare system is structurally incapable of building preventative medicine, why each dog-owner relationship is a "micro single-payer health care system," and how a quiet 2019 change to FDA regulation was the one-to-one cause of Loyal existing at all. ("If this pathway didn't exist, Loyal wouldn't exist. October 2019, I incorporated.") From there, the conversation widens. Celine lays out the Tesla-style master plan — save the dogs, save the world — that uses dog-drug revenue to fund human longevity work, escaping the discipline of biotech VC entirely. Ben presses her on AI in drug development (she's
A biotech startup is conducting a clinical trial on a daily beef-flavored pill designed to help dogs live healthier, longer lives, says Celine Halioua, founder of Loyal. #dogs #longevity #biotechnology
Loyal's CEO took a portfolio approach with their dog longevity drugs, despite it significantly increasing the startup's costs. Catch the full episode: Youtube.com/@UpstartsMedia Produced & edited by Eric Johnson from LightningPod
The question isn't if the first longevity drug gets approved – in almost every universe, it's when. That changes how investors think about the opportunity. Do you come in now and get the discount for bearing approval risk? Or wait until post-approval when the company can be more competitive on price, but so can everyone else trying to get into the deal?
When Loyal founder Celine Halioua told people she was building a dog longevity startup, they laughed in her face. Now she's running what could be the largest-ever clinical trial to extend canine lifespans — pursuing FDA approval for multiple drugs to help senior and large dogs live two years longer or more. Celine shares her unusual journey to raising $250 million for a startup that defies easy labels, her Upstart Moment taking her biggest fear head-on, and the example she hopes to set for another generation of women deep tech founders. Chapters: 0:00 Intro to Celine and Loyal 1:42 Celine’s origins in human longevity 12:44 Breaking Silicon Valley patterns 14:51 The largest clinical trial for pets 18:13 Handling founder highs and lows 20:53 Celine’s Upstart Moment 24:53 Overcoming her biggest fear 30:56 Finding the right people 34:29 Loyal’s healthier future 35:23 Setting a new example For more, visit https://www.upstartsmedia.com/ Season 1 of the Upstarts Podcast is presented by Me
Loyal just closed a $100 million Series C led by Age1, Laura Deming’s longevity fund, to advance LOY-002, a daily pill aimed at extending the healthy lifespan of senior dogs 🐶💊. The upcoming STAY study will be the largest animal health clinical trial ever, recruiting 1,300 dogs across 70 clinics. Success could mark the first FDA-approved drug targeting aging itself rather than a specific disease. Full Episode on YouTube, Spotify and Apple Podcast. Link in the comment. #LongevityTechnologyUnlocked #LongevityPodcast #LongevityBiotech #PetHealth #HealthyAging #LongevityTechnology
Sponsor: Stride Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science. Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount. Link: https://www.getstride.com/unlocked/ ______________________ In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore breakthroughs shaping healthspan and longevity, from pioneering longevity drugs for dogs to one-shot gene therapies for ALS, AI-driven longevity data platforms, and innovations in environmental detox. - Loyal, backed by Laura Deming’s Age1 Fund and other investors, raised $100 million Series C to advance LOY002, a daily pill aimed at extending the healthy lifespan of senior dogs. The drug has cleared two of three FDA hurdles, and its STAY trial will enroll 1,300 dogs across 70 clinics, potentially setting a r
Sam Kirschner sits down with Celine Halioua, Founder & CEO of Loyal, to discuss how she's building the first FDA-approved drug for lifespan extension — starting with dogs. With over $250M raised and major regulatory milestones cleared, Celine explains why dogs are the fastest path to a human longevity drug, how deep tech fundraising actually works, and what she's learned leading an ambitious biotech company through six years of uncertainty. 00:00 — Introduction 00:41 — From art school to neuroscience to founding Loyal 02:08 — The state of Loyal today: $250M+ raised, multi-product 03:36 — Fundraising as a U-shape: easy, hard, then easy again 06:07 — Milestone-based fundraising for deep tech vs. software 08:33 — Advice for deep tech founders on milestones that matter to investors 10:29 — The Series C narrative: de-risking biological uncertainty 13:10 — What comes after manufacturing approval 13:48 — Commercialization: building a pharma brand people love 16:42 — Multi-product strategy an
Te invitamos al webinar “Auditorías sin estrés: cómo usar la tecnología de forma inteligente para ganar tiempo y mejorar el rendimiento”, donde exploraremos estrategias prácticas para simplificar la preparación, ejecución y seguimiento de auditorías de calidad. En este encuentro, analizaremos cómo convertir las auditorías en una herramienta de mejora ¡y no en un motivo de estrés!: ✅ Cómo preparar la documentación de forma ágil y organizada ✅ Pros y contras de no estar digitalizados ✅ Rueda de Deming (PDCA) aplicada a la mejora continua ✅ Ejemplos prácticos en el software LOYAL: automatización, centralización y ahorro de tiempo 🗓️ Fecha: 13 de noviembre 🕒 Hora: 15:00 hs (ARG) – 15:00 hs (ARG) 💻 Plataforma: Google Meet 🎙️ Disertantes: - María Laura Rodríguez: bioquímica y consultora bromatológica con más de 20 años de experiencia en la industria alimentaria, representando a Innocuus - Cecilia Lupi: responsable del Área de Servicios en LOYAL Solutions, especialista en implementac
Celine Halioua is the Founder & CEO of Loyal - the first company to ever receive FDA approval to develop a drug to extend lifespan in dogs, and they have raised $125mm from Bain Capital Ventures, Khosla Ventures, First Round and others to do so. By building a blockbuster longevity drug for dugs, Loyal aims to lay the foundation for safe and effective longevity drugs in humans. In this interview, Celine describes her thesis that longevity drugs should be boring, what it means to create a new market, how charlatans put the whole longevity field at risk, and much more. We hope you enjoy this episode. Episode Links Substack: https://freeradicalspodcast.substack.com/p/making-dogs-live-longer-so-humans Apple Podcasts: https://podcasts.apple.com/us/podcast/celine-halioua-making-dogs-live-longer-so-humans-can-too/id1853729741?i=1000737184255 Spotify: https://open.spotify.com/episode/1iJGcwg30tkSG3MZTJtAfv?si=9jLplMJqQAu6D_vd1fYs1g Timestamps 00:00:00 - Intro 00:01:51 - Celine’s background
Celine Halioua is trying to do something no one’s ever pulled off: make dogs live longer and then use those skills to teach us how to extend human life too. Her company, Loyal, is close to bringing the first FDA-approved longevity drug to market, aimed at giving senior dogs one more healthy year. In this episode, we talk about the science, the clinical trials with 1,300 dogs, and why Celine believes the key to human aging might start at the vet’s office. We also get into the weirder corners of biotech culture — Silicon Valley’s longevity obsession, peptides, dog pills that smell like ramen, and why she thinks biotech needs more chaos and fewer “Boston graybeards.” It’s an honest, funny, and wildly sharp conversation about science, ambition, and the future of aging. Subscribe to watch more Core Memory videos https://www.youtube.com/@CoreMemoryVideos/videos Check out our podcasts https://www.youtube.com/@CoreMemoryPodcast https://www.corememory.com/podcast Find Ashlee Vance at www.c
From a child prodigy in a genetics lab to building a company that can pause life itself, Laura Deming has made a career out of chasing time. At just eight years old she became obsessed with aging. At eleven, she joined Cynthia Kenyon’s pioneering longevity lab. At seventeen, she launched The Longevity Fund—one of the first venture firms dedicated to extending human healthspan. Now, she’s tackling her boldest challenge yet: building a “pause button” for biology. As the co-founder of Until, Laura is developing reversible cryopreservation: the ability to cool living tissue to ultra-low temperatures, hold it there, and then bring it back fully functional. By achieving vitrification (the process of turning tissue into glass instead of ice), Until aims to make organ preservation, and eventually medical hibernation, a reality. *We cover:* • Why longevity was once stigmatized, and what changed to make it one of the most credible fields in biotech today • Why Until’s approach focuses on preser
Welcome back to another episode of The Room Podcast! This episode explores the fascinating correlation between **dog breeds** and their **dog life expectancy**. We sit down with Celine Halioua, Founder and CEO of Loyal, a biotech company pioneering FDA-approved longevity drugs for dogs. From a childhood surrounded by rescue animals to an academic journey through neuroscience, health economics, and venture capital, Celine’s path to entrepreneurship is as winding as it is inspiring. Today, Loyal is leading the charge in redefining what’s possible in veterinary medicine—aiming not just to treat disease, but to extend healthy lifespan itself. In this episode, Celine shares how her scientific curiosity about aging and her love for animals converged into a singular mission. She takes us behind the scenes on the founding story of Loyal—from a chance conversation around a campfire, to navigating the capital-intensive world of biotech, to winning over regulators and pet parents alike. Listener
This is Fusion Note — your weekly spark of resonant tech, lucid science, and beautifully strange ideas. This week’s spotlight is the Wachowskis — architects of The Matrix and Cloud Atlas, reminding us that beauty, truth, and community might just be what saves the world. Inside this week’s Fusion Note: ✈️💤 Vectis takes flight: Lockheed Martin unveils an autonomous “loyal wingman” drone, while Laura Deming raises $58 million for hibernation pods — AI skies meet cryosleep futures. ⚛️🤖 U.S.–China race: Fusion energy and humanoid robotics become the twin battlegrounds for global leadership. 💉🧬 Hope in health: A one-time gene therapy slows Huntington’s by 75%, and the FDA approves the first novel schizophrenia drug in 50 years. 🦠⏰ New cancer tools: Gut bacteria reprogrammed to attack tumors + circadian rhythms reframed as a hidden anti-cancer arsenal. 🌕🔭 Pop Space: Blue Origin’s “Blue Alchemist” designing lunar bases with moon dust and Artemis set for a 10-day Moon flyby in 202
Send us Fan Mail (https://www.buzzsprout.com/413041/fan_mail/new) We explore the cutting-edge science of extending dog lifespan through innovative drug development with Loyal (https://loyal.com/) founder and CEO Celine Halioua (https://x.com/celinehalioua) , who shares the company's groundbreaking approach to canine longevity and health. In Science News: • Cold water immersion after exercise shows no benefits for women despite its popularity among fitness influencers In Pet Science: • Brachycephalic dog and cat breeds now resemble each other more than their wild ancestors due to selective breeding Our Guest Speaks about: • Loyal's first drug mimics the longevity benefits of caloric restriction without reducing appetite • Large dog breeds age faster due to persistently high growth hormone levels that weren't naturally selected for • Loyal is conducting the largest animal health study ever with 1,300 dogs to test longevity interventions • The company hopes to bring their
(If you enjoyed this, please like and subscribe!) It was a pleasure to sit down this week with Josh Kopelman, one of the original architects of seed stage investing who continues to re-invent what it means to operate within venture. Josh co-founded First Round Capital, which has invested at the earliest stages in companies like Square, Uber, and Roblox. Some of Josh’s more recent investments include Notion, Pomelo Care, Loyal, and Perpay. Since First Round’s inception in 2004, Josh has invested in 500+ startups and has frequently made the Forbes “Midas List” which ranks the top 100 tech investors. Josh has been a founder three times (four if you include founding First Round). In 1992, while in college, he co-founded Infonautics Corporation – and took it public on NASDAQ in 1996. Josh co-founded Half.com in 1999 and led it to become one of the largest sellers of used books, movies and music in the world. Half.com was acquired by eBay in 2000, where Josh remained for three years. In
In this episode of The Eric Ries Show, I'm joined by Celine Halioua, founder and CEO of Loyal, a groundbreaking biotech startup developing drugs to extend dogs' healthspan and lifespan. Celine's journey combines her passion for animals with a bold scientific mission that looks beyond pets to potentially transform human longevity as well. Our conversation explores: • Why ambitious, moonshot visions can paradoxically make fundraising and team-building easier • The critical early pivot that positioned Loyal for its first drug approval • The undervalued power of listening deeply and asking the right questions • Loyal's philosophy of exceeding regulatory requirements to build trust and advance the field • Balancing the startup need for speed with scientific rigor and safety • How Celine's background led her to focus on the untapped potential of canine longevity • The competitive advantage of pursuing novel ideas before they become industry trends • Why founder conviction and scientific ex
This episode is brought to you by Warp. Don’t let payroll and compliance hold your startup back: visit https://joinwarp.com/peel to get started and receive a $1,000 gift card when you first run payroll. Celine Halioua is the founder and CEO of Loyal, a biotech company developing medicine to help dogs live longer and healthier lives. And dogs are just the start - Celine thinks Loyal could one day do the same for humans. She takes us inside what it’s like to build a biotech company from scratch. We talk through how Loyal’s longevity drugs work, the process of getting FDA approval, her biggest mistakes as a founder, how to approach building in a new market, lessons learned failing to raise her Series B, why rate of growth is all that matters in hiring, and almost not starting the company in the first place. Timestamps: (00:00) Preview (03:31) How a longevity drug works (06:01) Predictions around longevity (08:27) Why Celine cares so much about not failing (12:05) Differences between bi
Interview with Loyal CEO and Founder Celine Halioua for episode 37 of S³: https://youtu.be/J5TnnkEkN6s Startup: https://loyalfordogs.com/ 0:00 Dogs! 1:05 Celine’s founding inspiration 5:37 Research vs. spinning out 7:20 Celine’s superpower 8:20 Hardest technical challenge 10:14 Can bio revolutionize? 15:32 Stories from raising 18:56 Bio vs Hardtech vs Software 21:38 How do you think? 24:14 Founder learnings 26:38 Solo vs Cofounding 27:23 What deep tech gets wrong 32:01 Current life philosophy Blog ✍️ https://saturdaystartups.beehiiv.com/ Socials 📱 https://twitter.com/jasonjoyride 🐦 | https://www.instagram.com/jasonjoyride/ 📸 | https://www.linkedin.com/in/jason-carman-63b384199 👨🏼💼 | www.jasoncarman.com/s3 💻
Loyal is creating drugs for dogs to live longer & healthier lives. Last Friday they raised an additional $45M to bring their first longevity drug LOY-1 to market, we filmed with CEO and Founder Celine Halioua the next day for episode 37 of S³! 0:00 Drugs for dogs 0:44 What is IGF-1? 3:01 A first-ever for longevity 7:01 What Celine's learned 8:29 Next milestone 9:29 My thoughts Blog ✍️ https://saturdaystartups.beehiiv.com/ Socials 📱 https://twitter.com/jasonjoyride 🐦 | https://www.instagram.com/jasonjoyride/ 📸 | https://www.linkedin.com/in/jason-carman-63b384199 👨🏼💼 | www.jasoncarman.com/s3 💻 Our AMAZING S³ Patreon supporters: Alex Balfanz A B Tony Coffman
I brought two top Silicon Valley entrepreneurs working on extending lifespans on the Newcomer podcast this week. One of them is trying to help people live longer. The other, their dogs. James Peyer, the CEO of Cambrian, is buying up majority stakes in drugs that could combat a particular illness while showing promise for broader use among healthy humans. Meanwhile, Celine Halioua, the CEO of Loyal, is developing drugs to make dogs live longer. Fundamentally life extension, or longevity, is about finding drugs and treatments that can be given to healthy humans to help them live longer, healthier lives. Instead of just treating illnesses, entrepreneurs in the space want to find ways to stave off aging in already healthy people. The space has long been a fascination of mine. In February 2022, I profiled Elad Gil’s investments in an array of companies looking to make healthy humans live longer, healthier lives. The HBO show Silicon Valley helped popularize the idea that Silicon Va
Camille Ricketts began her career in journalism, at the Wall Street Journal, in 2006. In 2010 she joined Tesla, where she worked in communications alongside Elon Musk. She transitioned into marketing and became the Head of Content and Marketing at First Round Capital and then went on to become the very first marketing hire at Notion. In today’s episode, we dig into community-led growth—what it is, and when and how to pursue it. We get super-specific on how Notion championed their most loyal users and built a passionate community, and the incredible outcome it had for the company’s growth. We also talk about how to create great content, and how content can drive growth for your business and brand. — Find the full transcript here: https://www.lennysnewsletter.com/p/how-notion-leveraged-community-to — Thank you to our wonderful sponsors for supporting this podcast: • Eppo—Run reliable, impactful experiments: https://www.geteppo.com/ • Flatfile—A CSV importer that says yes instead of
Fauna Bio co-founders Ashley Zehnder, PhD, and Katie Grabek, PhD, and Celine Halioua, PhD, founder and chief executive officer of Loyal share their experiences and insights in launching and building successful life science startups.
We are incredibly excited to release our last episode from the Edventure Emerge series, with none other than Celine Halioua. Celine is the founder of biotech company, Loyal, which has raised over $38M in VC funding for its mission to develop drugs specifically designed to extend the healthspan and lifespan of dogs (and hopefully, one day, humans!). She was previously Chief of Staff to Laura Demming at the Longevity Fund. Tune into her riveting conversation with Rahul Rana and Jared Tumiel (who joins us half way through the episode), as they discuss the science of ageing, the role of biotech, and how Loyal is taking a novel approach. Jared is a multidisciplinary medical doctor from South Africa, a fellow of OnDeck Longevity Biotech and the host of "Bit of Tangent", a rationalist podcast exploring ideas in Science, Philosophy, Artificial Intelligence, and Medicine. Rahul Rana is the author of Making Moonshots, a deep dive into the mindsets, philosophies, and strategies conducive to bui
Celine Halioua, who studied neuroscience at the University of Texas, Austin, and economics of gene therapeutics at Oxford, founded San Francisco– based biotech Cellular Longevity (known as Loyal) in 2019 to identify compounds that help prevent undue aging and cancer in dogs, which could also potentially help humans. One key advantage: It’s easier to get experimental drugs approved for the veterinary market than for humans. Her first anti-aging drug entering clinical trials next year targets a cellular mechanism hypothesized to mitigate mental and physical decline associated with age. The pre-revenue company has raised over $38 million in venture capital. “There’s never been a drug approved for aging for any species, dog or human,” Halioua says. “My core goal in life is to get the first drug approved.” We published the first edition of the Forbes 30 Under 30 a decade ago, with one clear goal: to identify the new guard, the young innovators, trailblazers and disruptors remaking our worl
Meet Celine Halioua, founder and CEO of Loyal, a biotech startup developing drugs to extend dog lifespan. In this episode of Lady Scientist Podcast, Celine reveals how a single cold email landed her an internship and then later a full-time job with the Longevity Fund, a venture capital firm based in San Francisco. This was the career shift that launched her into the biotech space where she later founded Loyal, which has raised $27 million and has already completed its first clinical study! You can find Celine at https://www.loyalfordogs.com/. Support the podcast by subscribing to our channels, signing up for our newsletter, and leaving a review or comment. Thank you for listening! Support our podcast through Patreon and get #LSP swag: https://www.patreon.com/ladyscientist... Episode Highlights: 3:18 Celine made the difficult decision to leave Oxford, where she was previously a graduate student studying neuroscience and went all-in with Longevity. 8:05 Celine speaks to the signific
The future of aging, notes on being a female founder, and a deep dive into the biotech industry. Celine Halioua has a background in neuroscience and experience in a venture capital firm. And she loves dogs. These combined have got her to where she is today - the founder and CEO of Loyal, a biotech startup developing drugs to extend a dog's lifespan. Did you know that dogs are considered the best model of human aging? What if we could make human’s best friend live longer (and whilst we’re at it, get insight to prevent age-related diseases in humans too). In this podcast with Niko Woischnik, founder of TOA, they discuss how to get ahead in the Silicon Valley biotech world (with a very detailed tech framework on her website - link below), why she’s focussing on dogs for age prevention, and the strengths you need to become a founder. She also discusses her difficulties in her career up to here including difficulty dropping out of Oxford University, how balancing work and life is near to
Aubrey de Grey on Leave After Sexual Harassment Allegations Disclaimer : Copyright Disclaimer under section 107 of the Copyright Act 1976, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, education and research. Fair use is a use permitted by copyright statute that might otherwise be infringing. Non-profit, educational or personal use tips the balance in favor of fair use. https://tinyurl.com/TodaySciencology #Science #Technology #Invention Aubrey de Grey, a self-taught gerontologist who has promoted the idea that aging is a preventable, pathological phenomenon, has been placed on leave by the research foundation he cofounded and an investigation into alleged sexual harassment is underway, STAT reports today (August 11). Last night, the female founders of two companies aimed at healthy life span extension, Laura Deming of the Longevity Fund and Celine Halioua of Loyal, relayed experiences they say they had with de
Aubrey de Grey on Leave After Sexual Harassment Allegations Disclaimer : Copyright Disclaimer under section 107 of the Copyright Act 1976, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, education and research. Fair use is a use permitted by copyright statute that might otherwise be infringing. Non-profit, educational or personal use tips the balance in favor of fair use. https://tinyurl.com/TodaySciencology #Science #Technology #Invention Aubrey de Grey, a self-taught gerontologist who has promoted the idea that aging is a preventable, pathological phenomenon, has been placed on leave by the research foundation he cofounded and an investigation into alleged sexual harassment is underway, STAT reports today (August 11). Last night, the female founders of two companies aimed at healthy life span extension, Laura Deming of the Longevity Fund and Celine Halioua of Loyal, relayed experiences they say they had with de
Subscribe to our Substack https://thedeepend.substack.com/ where we’ll be sharing notes from our episodes, links to further reading and other announcements. -- We talk with Celine Halioua, founder and CEO of Loyal — a startup that is developing drugs to extend dog lifespan. Celine was in the second cohort of the On Deck Founder fellowship and recently announced an $11M raise — one of the largest seed rounds ever for a female solo founder. Though Loyal’s immediate project is longevity for dogs, Celine’s long-term goal is to build the “SpaceX of Aging” and to make the goal of extending human lifespan as prominent in the public mind as the prospect of interplanetary travel. We discuss: - When the straight path is not the effective path - Redefining the narrative around longevity - How to think about/define lifespan extension - Why aging isn’t consider a disease—but it should be - Building the SpaceX for aging - How to find the thing you’re uniquely good at building - On deciding to go
(22 May 2007) Program version at 11:11:27 HEADLINE: Idol Finale: Hometown fans hail Blake Lewis (tv-american-idol) CAPTION: 'American Idol' finalists Jordin Sparks and Blake Lewis are attractive, talented and have millions of adoring fans. (May 22) [Notes:ANCHOR VOICE] NB. This is a voiceover transcript, not a full shotlist: Everywhere you look in the small town of Bothell, Washington, there are signs of support for American Idol finalist Blake Lewis who grew up here and still has strong ties to the area. SOT: "the Pacific Northwest has an enormously proud and rich musical tradition. We have a lot of independent artists. A lot of people who have done great in alternative music and rap and Blake, I think, represents the proudest part of that tradition. I think one of the things that you'll notice in the Puget sound area and in Bothell particularly that independent artist, instead of being like, ooo, American idol that's so corporate, they've totally rallied arou
Access the full length version at http://bit.ly/EmotionalBrandingSeminar or see a full list of our programs at https://seminarsondemand.com/seminars/ Service today is typical and transactional. People look at customers as an opportunity for a sale, rather than a meaningful interaction that will turn that customer into a loyal fan for life. Customer service is dying because people simply stopped looking at other people as fellow human beings. In this thought-provoking fast paced program, brand building expert Scott Deming uncovers key principles for creating experiences that keep people coming back and telling others about you. He'll show proof positive that advertising is simply awareness. It's sincere caring and extraordinary emotional experiences that are the key to sustainable personal and professional success. Whether you're leading a team or serving people on the front line, this program will inspire you to perform at a whole new level. Scott Deming is an internationally sought-
Karnofsky Award Winner Honors Mentors through Gift to Conquer Cancer Foundation - The ASCO Post --> --> Toggle navigation About About The ASCO Post Editorial Board Rights and Permissions Contact Subscribe News FDA Update Journal Spotlight Expert's Corner In the Clinic View By Issue View All Meetings ASCO 2026 ESTRO 2026 AACR 2026 EBCC15 2026 ASCO GU Calendar View All Topics AI in Oncology Breast Cancer Lung Cancer Prostate Cancer Lymphoma Cardio-oncology View All Perspectives Charles Bennett and colleagues: The Inflation Reduction Act and Ibrutinib Derek Raghavan: How I Discuss the Curren … deos Newsreels Video Roundtables Podcasts Subscribe --> Advertisement Karnofsky Award Winner Honors Mentors through Gift to Conquer Cancer Foundation By ASCO November 1, 2012 Advertisement Kanti R. Rai, MD , and his wife Susan have been loyal donors to the Conquer Cancer Foundation for the past 9 years, but in 2012, a momentous occasion in his career inspired Dr. Rai to make a unique gift. A Moment of Reflection In the spring of 2012, Dr. Rai, an internationally recognized ex … n adult leukemia, learned that he would receive the David A. Karnofsky Memorial Award, ASCO’s highest scientific honor, at the ASCO Annual Meeting. The Karnofsky Award is presented in recognition of innovative clinical research and developments that have changed the way oncologists think about the general practice of oncology. For Dr. Rai, Chief of Chronic Lymphocytic Leukemia (CLL) Research and Treatment Program at North Shore–Long Island Jewish (LIJ) Health System, Joel Fin … cal Research, it was a moment for reflection. “When I was first notified of the award I felt humbled and honored. I started to reflect upon how I reached where I have reached in my career, and realized that it was important to remember and honor my two mentors,” he said. For Dr. Rai, that meant finding a way to honor Arthur Sawitsky, MD , and Eugene P. Cronkite, MD . It was Dr. Sawitsky who first taught Dr. Rai “to look at blood and bone marrow under the microscope, diagnose … ing relationships in its programs. The Foundation’s flagship Young Investigator Award (YIA) and Career Development Award (CDA) programs have a critical mentorship component—with each recipient pursuing his or her research under the guidance of an experienced mentor. Programs like the International Development and Education Award (IDEA), and the L
Heffernan: GSA's Emily Murphy vies for lead among Trump's loyal liars - Los Angeles Times News Home Page California Election 2024 Housing & Homelessness Politics Science & Medicine World & Nation Business Artificial Intelligence Autos Jobs, Labor & Workplace Real Estate Technology and the Internet California California Politics Earthquakes Education Housing & Homelessness L.A. Influential L.A. Politics Mental Health Climate & Environment Climate Change Water & Drought Entertainment & Arts Arts Books Stand-Up Comedy Hollywood Inc. The Envelope (Awards) … nable a layout that focuses on the article. Focus mode Show Search Search Query Submit Search Politics Trump Administration California Politics L.A. Politics View All Advertisement Voices Virginia Heffernan The GSA administrator vies for the lead among Trump’s loyal liars GSA Administrator Emily Murphy, shown in 2019, has not acknowledged President-elect Joe Biden’s victory, a holdup that could impede his transition team. (Bill Clark / CQ-Roll Call) By Virginia Heffern
Where are the world’s most loyal readers? Hint: It’s not North America Login close E-mail Password (Forgot Password?) Login is restricted to DCN Publisher Members. If you are a DCN Member and don't have an account, register here . Forgot Password close Username or E-mail You will receive a link to create a new password via email. Register Login OPA InContext Advertising AI Audiences Policy Research Revenue Video Research DCN Research Industry Research Public Policy Events DCN Events Where is DCN Speaking? Membership Join DCN Members Supporters About Overview Board of Directors Exec Committee D
Loyal | Careers Skip to main content One step closer to a longevity drug: LOY-002 hits key FDA milestone. Read more → Products For vets Overview Continuing education Resources For dog owners Clinical trials Blog Products Discover our longevity drugs and the principles guiding their development. Overview for vets Clinical resources, education, and insights on aging and treatments. Continuing education Stay current with the latest science on canine aging and longevity medicine. Resources for vets Access tools, data, and guidance to support clinical decision-making. For dog owners Learn about agi … cal, dental and vision) for you and your dependents $1000 home office equipment stipend $250/month wellness budget (gym, cleaners, spa, food) $1200/year learning budget (books, courses, etc.) All 3-day weekends turned into 4-day weekends 🎉 Unlimited vacation and paid holidays Paw-ternity leave — adopt a dog and get a day off with your new family member 🐶 Annual company retreat at beautiful locations across the country (recently: Tahoe, Cape Cod) Flexible remote work opportu … Cape Cod) Flexible remote work opportunities Competitive salary Equity options grant Tiberia Age 6 Open roles Clinical Development Senior Director, Clinical Development Remote - US Apply Executive Chief Operating Officer Remote - US Apply G&A Vice President, Finance Remote - US Apply Regulation & Quality Director, Regulatory Affairs - Clinical Remote - US Apply All Departments Clinical Development Executive G&A Regulation & Quality Be the first to know when w
Loyal: $22 Million (Series B-2) Raised For Clinical-Stage Animal Health Platform VC PE M&A Asset Management Law Firms Profiles Contact × Search Pulse 2.0 Loyal: $22 Million (Series B-2) Raised For Clinical-Stage Animal Health Platform By Amit Chowdhry • Feb 28, 2025 Loyal: $22 Million (Series B-2) Raised For Clinical-Stage Animal Health Platform Loyal, a clinical-stage animal health company developing longevity drugs for dogs, announced that the FDA’s Center for Veterinary Medicine has accepted the Reasonable Expectation of Effectiveness (RXE) section of its conditional approval app … has raised a $22 million B-2 round from Valor Equity Partners and Collaborative Fund, and others, in addition to its $45 million Series B in 2024. This brings the total investment in Loyal’s to over $150 million. Jonathan Shulkin, Partner and Co-President at Valor Equity Partners, is joining the company’s Board of Directors. The FDA’s Center for Veterinary Medicine determined that Loyal’s data provides reasonable expectation of LOY-002’s intended effect of e
Instagram Instagram Log In Sign Up Close Never miss a post from loyalfordogs Sign up for Instagram to stay in the loop. Sign up Log in loyalfordogs • Follow More options loyalfordogs 1w Modern medicine treats diseases one-by-one, but what if aging itself is the root cause? The A-Word: The Future of Aging follows Loyal Founder & CEO Celine Halioua in her journey to develop the first FDA-approved longevity drug and other scientists racing to extend lifespan. Created by Emmy-winning filmmakers, The A-Word tells the story of how dogs — and people — may be on the cusp of a new biotech revolutio … nzo.vjc 1w i plan to live forever with @loyalfordogs in my @fundrise innovation fund portfolio (ticker #VCX ) Like Reply Like 35 Comment 2 Share Save May 20 Log in to like or comment. More posts from loyalfordogs Carousel Carousel Clip Clip Clip Carousel Clip See more posts Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsc
Meet the CEO and Founder of Loyal, a biotech startup with a mission to increase canine lifespan. Broadcasting our next incredible speaker, Celine Halioua! Celine Halioua is the CEO and Founder of Loyal, a biotech startup developing drugs to increase healthspan and the period of life spent in good health for canines. Before founding Loyal, she was a DPhil student at Oxford studying the economics of gene therapy. She sought to understand the incentives of different healthcare systems in providing curative therapeutics. This fed a broader interest in health equality that led her to longevity and … ropped out of her DPhil in her final year to join Laura Deming at the Longevity Fund, one of the pioneering early investors in the longevity field, before founding Loyal in 2019 at the age of 25. Attend Celine Halioua’s talk live at TEDxBerkeley 2023 by purchasing a ticket at https://www.tedxberkeley.org/! We understand the uncertainty of these times; hence, we will offer full refunds for any tickets purchased up until the week before the event and ticket transfers will be pe
SALT — Celine Halioua Home About Events About Abu Dhabi '24 New York '24 Jackson Hole '24 Singapore '24 Library Talks About Season 3 Season 2 Season 1 Contact Us Home About Events About Abu Dhabi '24 New York '24 Jackson Hole '24 Singapore '24 Library Talks About Season 3 Season 2 Season 1 Contact Us Joe Eletto April 24, 2023 Speaker | NY23 Celine Halioua Joe Eletto April 24, 2023 Speaker | NY23 Chief Executive Officer & Founder, Loyal Celine Halioua is the CEO and Founder of Loyal, a biotech startup developing drugs to increase healthspan, the period of life spent in good health. Be … preventative medicine. Celine left Oxford to join Laura Deming at The Longevity Fund, one of the pioneering early investors in the longevity field, before founding Loyal in 2019 at the age of 25. Loyal is developing the first FDA-approved drugs explicitly intended to extend lifespan and health span. On the path to FDA approval, Celine and her team are running clinical trials that objectively and robustly demonstrates that Loyal's drug extends dogs’ healthy lifespan, and does
Loyal’s Celine Halioua: From D… - The Upstarts Podcast - Apple Podcasts Search Home New Top Charts Search February 19 38 min Loyal’s Celine Halioua: From Defying Doubters To Pioneering Dog Longevity The Upstarts Podcast Play When Loyal founder Celine Halioua told people she was building a dog longevity startup, they laughed in her face. Now she's running what could be the largest-ever clinical trial to extend canine lifespans — pursuing FDA approval for multiple drugs to help senior and large dogs live two years longer or more. Celine shares her unusual journey to raising $250 million for a st
Loyal - We’re excited to share that our CEO and Founder... Facebook Вход Публикация Loyal Loyal 24 июнь 2024 г. · Поделился/-ась с Доступно всем We’re excited to share that our CEO and Founder Celine Halioua will be speaking at the #AspenIdeas Festival tomorrow: → ‘New Lease on Life: Is Dog Longevity the Key to Ours?’ on June 25 at 1:50 p.m. MT She's joining Daniel Promislow and Elliot Gerson and will share insights on how Loyal is helping dogs live longer, healthier lives. Aspen Ideas Festival Все реакции: 5 Поставить "Нравится" Комментировать
Loyal Source | Government Contract Vehicles: GSA, VA, DHA, ICE, Navy Skip to content Our Capabilities Search Jobs Join our Network Company About Loyal Source Our Culture Our Philanthropy Our Leadership Healthcare Solutions Expeditionary Medical Healthcare IT Occupational Health Global Mission Solutions Engineering Services Training Services Logistics and Supply Chain Workforce Solutions Department of War and Veteran Affairs Services Technical Workforce Solutions Correctional Solutions Human Performance and Preservation of the Force and Families (POTFF) Human Performance and Preservation of the … ied Healthcare Staffing Services General Services Administration (GSA) Multiple Award Schedule (GSA MAS) Defense Health Agency, Medical Q-Coded Support and Services Next Generation Unrestricted (MQS2-NG) Immigration and Customs Enforcement, Medical Staffing Services at ICE Detention Facilities Across the United States General Services Administration (GSA) OASIS+ Multi Agency Contract Unrestricted (Management and Advisory Domain) United States Navy, Seaport NextGen United Stat … ates Navy, Seaport NextGen United States Navy, Worldwide Expeditionary Multiple Award Contract 2.0 (WEXMAC 2.0) 12612 Challenger Parkway, Ste. 365 Orlando, Florida 32826 407-306-8441 888-263-3208 All media inquiries should be directed to [email protected] 𝕏 --> Privacy Policy | Terms and Conditions Healthcare Solutions Expeditionary Medical Healthcare IT Medical Disability Exams Occupational Health Global Mission Solutions Engineering Services Training Services … logy strategy and enterprise systems. Jeff oversees all facets of IT, including application support, ATS systems, advanced analytics, and infrastructure security. His focus is on building scalable, secure, and future-ready IT solutions that support company growth. Jeff’s leadership ensures Loyal Source remains technologically agile in an ever-evolving landscape. × Leigh Pace COO Leigh Pace has over 20 years of experience building and leading high-performing operational teams … ns. × Phone This field is for validation purposes and should be left unchanged. Apply For Job Complete your personal information below to arrange your first stage interview. Name (Required) First Last Email (Required) Phone Number (Required) In which city do you live? (Required) In which state do you live? (Required) Select your State Alabama Ala
GSA eLibrary Contractor Information An official website of the United States government Here's how you know Here's how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. Search: | all the words any of the words exact phrase (Vendors) How to change your company information System Notice: eLibrary is experiencing an issue with MAS 8(a) Po
Instagram Instagram Log In Sign Up Close Never miss a post from aaicdrones Sign up for Instagram to stay in the loop. Sign up Log in aaicdrones • Follow Hagerstown Md More options aaicdrones 4d “Trust is built with consistency.” – Lincoln Chafee At AAIC, we bring over 25 years of experience in drone operation and aerial photography, surpassing most of our competitors in longevity. Our extensive portfolio showcases a collection of stunning images and videos, reflecting our commitment to quality and creativity. We are proud to have earned the trust and satisfaction of a diverse and loyal client
Vampire nobles and their... - Archer Print & Paint Studio Facebook Вход Публикация Archer Print & Paint Studio Archer Print & Paint Studio 22 ноябрь 2023 г. · Поделился/-ась с Доступно всем Vampire nobles and their loyal knights have descended upon the locals, laying waste to the populace and leaving nothing in their wake! No mystery boxes, no duplicates, no guessing - these 10 resin miniatures are what's coming in December's box. $49.99/month (3 and 6 month subscribers get a discount!), free U.S. shipping, an extra free mini for new subscribers, and 10% off coupon for al
Instagram Instagram Log In Sign Up Close Never miss a post from biokansas Sign up for Instagram to stay in the loop. Sign up Log in biokansas • Follow More options biokansas 107w We are honored to have Hill's Pet Nutrition as a loyal member and sponsor of BioKansas events! A big thanks to Hill's for their generosity. For a chance to win a "Skin and Sun Basket", courtesy of Hill's Pet Nutrition, and meet the Hill's team, register your team for the BioKansas Golf Scramble! https://ow.ly/loq350RAQTE Load more comments No comments yet. Start the conversation. Like 1 C
Aging Archives - Freethink Skip to content Open the Main Navigation Menu Open the Main Navigation Menu Freethink Subscribe Open the Main Navigation Menu Open the Main Navigation Menu Freethink Primary Menu About Careers For Brands Privacy Policy All Videos Challenges Collections It’s the news, reimagined. Move the World Skoll | Rethinking Possible Sorry to see you go! T-Minus Thank You Thank You Video Library Field: Aging Aging Longevity progress is real. So are the scams. Longevity is in a paradoxical place at the moment, with anti-aging influencers misrepresenting real progress in orde … Saloni Dattani and Lucas Rodés-Guirao | Our World in Data Aging Biggest science prize in history aims to extend human healthspan by a decade Do humans have an ethical obligation to “die young”? Maybe not in the way you think, says bioethicist Raiany Romanni. Raiany Romanni Aging First anti-aging drug for dogs nears approval The FDA is a major step closer to approving biotech company Loyal's LOY-001, the first anti-aging drug for dogs. Kristin Houser Death Study finds exactly
Instagram Instagram Log In Sign Up Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภาษาไทย Filipino Türkçe 中文(简体) 中文(台灣) বাংলা ગુજરાતી हिन्दी Hrvatski Magyar ಕನ್ನಡ മലയാളം मराठी नेपाली ਪੰਜਾਬੀ සිංහල Slovenčina தமிழ் తెలుగు اردو Tiếng
Scientist Aubrey de Grey put on leave over sexual harassment allegations Skip to Main Content research Cancer ASCO Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT@ASCO Search Log In Try STAT+ My Account Home News Latest STAT10 Business Biotech Pharma Health Tech Health Insurance Hospitals Medical Devices Washing … nsion. On Tuesday night, Laura Deming, the 27-year-old founder of the Longevity Fund , and Celine Halioua, the 26-year-old founder and CEO of Loyal , a biotech startup developing drugs to help dogs live longer, posted accounts on their blogs and to Twitter of experiences they had with de Grey as young scientists trying to gain a foothold in the field. Advertisement De Grey denied the allegations in a post on Facebook, and SENS issued a statement saying he had been placed on l … @MeganMolteni @mmolteni.bsky.social linkedin.com/in/meganmolteni/ Tags aging To submit a correction request, please visit our Contact Us page . Trending The virtual end of the doctor’s office waiting room The virtual end of the doctor’s office waiting room For prostate cancer patients set on surgery, new hormone… For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds Consumer health advocate Sid Wolfe was a thorn in… C
Anti-aging foundation's CEO left amid probe of Aubrey de Grey | STAT Skip to Main Content HHS addiction Politics Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home News Latest STAT10 Business Biotech Pharma Health Tech Health Insurance Hospitals Medical Devices Wa … hey told STAT in interviews. On Tuesday, Laura Deming, the founder of Longevity Fund , and Celine Halioua, CEO of Loyal, published a pair of blog posts accusing de Grey of making inappropriate remarks to them early in their careers, when he was serving as their mentor. Deming was just 17 years old at the time. The women also alleged that SENS had known about their experiences since June and looked the other way while de Grey helped the organization raise more than $20 million … @MeganMolteni @mmolteni.bsky.social linkedin.com/in/meganmolteni/ Tags aging To submit a correction request, please visit our Contact Us page . Trending Alcohol study discarded by Trump officials is published in… Alcohol study discarded by Trump officials is published in scientific journal Lawmakers promised cancer patients would be protected from Medicaid… Lawmakers promised cancer patients would be protected from Medicaid cuts. Now CMS says otherwise Fueling t
Loyal: pursuing longer, healthier lives for dogs [email protected] +91 8874569874 Hours : Opens 10:00 AM To 07:00 PM The Genetic Link The Microbiome Snapshot Molecules, Microbes and Multiomics Webinars The Genetic Link Welcome to The Genetic Link, a blog providing new insights into DNA and RNA sample collection by DNA Genotek. DNA Genotek is a subsidiary of OraSure Technologies, Inc. Read More Human Genomics loyal Loyal: pursuing longer, healthier lives for dogs Read More → Categories All blogs (204) Customer stories (92) Industry & product news (65) Sample collection/recruitment (64)
Loyal Skip to main content One step closer to a longevity drug: LOY-002 hits key FDA milestone. Read more → Products For vets Overview Continuing education Resources For dog owners Clinical trials Blog Products Discover our longevity drugs and the principles guiding their development. Overview for vets Clinical resources, education, and insights on aging and treatments. Continuing education Stay current with the latest science on canine aging and longevity medicine. Resources for vets Access tools, data, and guidance to support clinical decision-making. For dog owners Learn about aging, safety
Not just for big dogs! Our senior dog program receives preliminary FDA efficacy acceptance (RXE) Skip to main content Products For vets Overview Continuing education Resources For dog owners Clinical trials Blog Products Discover our longevity drugs and the principles guiding their development. Overview for vets Clinical resources, education, and insights on aging and treatments. Continuing education Stay current with the latest science on canine aging and longevity medicine. Resources for vets Access tools, data, and guidance to support clinical decision-making. For dog owners Learn about agi
Linda Rhodes joins the Loyal Board of Directors | Celine Halioua LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Priv
We’re excited to announce that Linda Rhodes, VMD, PhD has joined our Board of Directors. Dr. Rhodes is a scientist, veterinarian, entrepreneur, and leader in animal health, and we’re lucky to welcome… | Loyal LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any ti
Linda Rhodes joins the Loyal Board of Directors Skip to main content Products For vets Overview Continuing education Resources For dog owners Clinical trials Blog Products Discover our longevity drugs and the principles guiding their development. Overview for vets Clinical resources, education, and insights on aging and treatments. Continuing education Stay current with the latest science on canine aging and longevity medicine. Resources for vets Access tools, data, and guidance to support clinical decision-making. For dog owners Learn about aging, safety, and how to care for dogs as they grow
犬类长寿药物研发商Loyal筹集了1亿美元C轮融资，用于推进首款犬类长寿药物的发展-动脉网 APP 扫码下载 产业链接 公众号矩阵 动脉网 动脉新医药 动脉橙果局 产业链接 VBEF发布 动脉生物制造 透皮技术创新联盟TTIA 动脉智库 活动会议 2025数字疗法大会 CSGCT第二届中国细胞与基因治疗大会 2026未来医疗100强大会 2025VBEF直播回放&百强榜单 全部活动 解决方案 动脉AI 搜索 EN 登录 首页 情报 原创 专题 报告 链接 直播 活动 动脉网APP 扫码下载 犬类长寿药物研发商Loyal筹集了1亿美元C轮融资，用于推进首款犬类长寿药物的发展 Loyal Raises $100M Series C, Led by age1, to Advance the First Canine Longevity Drug vcaonline 等信源发布 2026-02-11 23:14 可切换为仅中文 微信扫码分享 Loyal Raises $100M Series C, Led by age1, to Advance the First Canine Longevity Drug Loyal 在 age1 领投的 C 轮融资中筹集了 1 亿美元，用于推进首个犬类长寿药物的发展。 With participa … 100M in Series C funding. age1, the next generation of Laura Deming’s Longevity Fund, led the round. Baillie Gifford also participated alongside existing investors, bringing the total investment in Loyal to over $250M since its founding in late 2019.. 旧金山，2026年2月11日 —— 致力于开发延长犬类寿命药物的临床阶段动物健康公司Loyal今天宣布，已在C轮融资中筹集了1亿美元。Laura Deming的Longevity Fund下一代基金age1领投了本轮。Baillie Gifford与现有投资者共同参与，使Loyal自2019年底成立以来的总投资额超过了2.5亿美元。 “Our driving purpose at Loyal is to help dogs live longer, h … complete, Loyal has satisfied two of the three major requirements for LOY-002’s application for Expanded Conditional Approval (XCA). LOY-002 是一种处方每日药丸，是 Loyal 公司的主要项目，旨在通过主动针对衰老的潜在代谢驱动因素，延长老年狗的健康寿命。随着“合理有效性预期”（RXE）和“目标动物安全性”（TAS）部分的完成，Loyal 已满足了 LOY-002 申请扩展条件批准（XCA）的三个主要要求中的两个。 If approved, LOY-002 stands to be the first FDA-approved drug for lifespan extension itself in any species.. 如果获得批准，LOY-002 将成为首个被 FDA 批准的用于延长任何物种寿命的药物。 “I’ve been incredibly lucky to know Celine sinc … DA Expanded Conditional Approval (XCA) is in progress, and the company plans to submit it for review later this year.. 随着Loyal持续推进其首款药物研发并扩充产品组合，新资金将支持公司扩大团队、建立分销渠道，并为其首款延长犬类寿命的药物上市做准备。美国食品药品监督管理局（FDA）扩大条件性批准（XCA）的最后一个主要要求正在进展中，该公司计划在今年晚些时候提交审核。 “Celine and the team are redefining how preventive care is approached in veterinary medicine,” said Tom Slater, partner at Baillie Gifford. “Helping dogs live longer, healthier lives matters to many families. By combining scientific r … r, Loyal has completed two of three major requirements needed for LOY-002’s XCA application and market launch and also completed enrollment in its pivotal trial, the STAY study, which is following 1,300 dogs across 70 veterinary clinics nationwide — the largest clinical trial in the history of veterinary medicine. 这笔融资的到来正值Loyal在LOY-002的XCA申请方面取得
How To Raise $125M Pre-Revenue and Why Harder Can Be Easier | Celine Halioua (Loyal) Mission Listings LISTINGS Partner with LTSE Listed Companies Listing Standards How to List FAQs Listed Company Resources Trading TRADING Why Trade on LTSE Platform Capabilities Trading Resources Fee Schedule & Incentives Membership Trading Schedule Product Data REGULATION Overview LTSE Rules Governance NMS Plans 605 Reports Disciplinary Actions Private Markets PRivate Markets LTSE Private Markets Solutions Late-Stage Private Companies Long-Term Investors Private Markets Insights News & Insights NEWS &a … g on LinkedIn: https://www.linkedin.com/in/laura-deming-b255362a/ The Longevity Fund: https://longevity.vc/ Researchers Identify Gene Involved in Dog Size: https://www.genome.gov/25520294/2007-release-researchers-identify-gene-involved-in-dog-size Caloric Restriction in Humans: Impact on Physiological, Psychological, and Behavioral Outcomes: https://pmc.ncbi.nlm.nih.gov/articles/PMC3014770/ Michael Nielsen’s website: https://michaelnielsen.org/ Navigating Silicon Valley as a … g on LinkedIn: https://www.linkedin.com/in/laura-deming-b255362a/ The Longevity Fund: https://longevity.vc/ Researchers Identify Gene Involved in Dog Size: https://www.genome.gov/25520294/2007-release-researchers-identify-gene-involved-in-dog-size Caloric Restriction in Humans: Impact on Physiological, Psychological, and Behavioral Outcomes: https://pmc.ncbi.nlm.nih.gov/articles/PMC3014770/ Michael Nielsen’s website: https://michaelnielsen.org/ Navigating Silicon Valley as a
Instagram Instagram Log In Sign Up Close Never miss a post from longevity.technology Sign up for Instagram to stay in the loop. Sign up Log in longevity.technology • Follow More options longevity.technology 16w 🎙️ $100M Raised to Extend Healthy Lifespan of Dogs ㅤ Loyal just closed a $100 million Series C led by Age1, Laura Deming’s longevity fund, to advance LOY-002, a daily pill aimed at extending the healthy lifespan of senior dogs 🐶💊. The upcoming STAY study will be the largest animal health clinical trial ever, recruiting 1,300 dogs across 70 clinics. Success could mark the first FDA-ap
--> Laura Deming top of page HOME EVENTS LIC in Gstaad 2026 LIC in Gstaad 2025 LIC in Gstaad 2024 LIC in Gstaad 2023 LIC in Gstaad 2022 LIC (Virtual) 2021 LIC (Virtual) 2020 LIL in Davos 2026 LIL in Davos 2025 LIL in Davos 2024 LIL in Davos 2023 LIL in Davos 2022 XPRIZE Investor Summit 2025 TEAM PRESS LI News CONTACT More Use tab to navigate through the menu items. < Back Laura Deming CEO, Cradle, Cofounder & Venture Partner, age1 and Founder of Longevity Fund When she was eight years old, Laura Deming realized that we were all going to die of a condition called aging. Ever since, her d … by Peter Thiel to dropout to found the first longevity-focused venture capital fund, Longevity Fund (5 IPOs across 3 funds with $37 AUM, over a billion in follow-on funding raised, and top-decile DPI). Now, Laura is the cofounder and a Venture Partner at age1, named after her 3rd fund that produced companies such as Loyal, Fauna Bio, Gordian Biotechnology, Rubedo Life Sciences, etc. age1 is a new $50M fund with cofounder Alex Colville devoted to catalyzing early-stage longev
$125M to extend dog lifespan Skip to main content Products For vets Overview Continuing education Resources For dog owners Clinical trials Blog Products Discover our longevity drugs and the principles guiding their development. Overview for vets Clinical resources, education, and insights on aging and treatments. Continuing education Stay current with the latest science on canine aging and longevity medicine. Resources for vets Access tools, data, and guidance to support clinical decision-making. For dog owners Learn about aging, safety, and how to care for dogs as they grow older. Clinical tr … (Greg Rosen), Quiet Capital (David Greenbaum + Daniel Gruneberg), Collaborative Fund (Craig Shapiro), and Todd & Rahul, doubled or tripled down on their previous investments in the company. The round was near 2X oversubscribed and at a significant markup to our 2021 Series A. 1 This new capital fuels us to very hopefully bring the first FDA-approved lifespan extension drug to market. 2 We have the data, the team, and the path forward — this capital was the last puzzle pie
FDA Center for Veterinary Medicine agrees Loyal’s data supports reasonable expectation of effectiveness for large dog lifespan extension Skip to main content Products For vets Overview Continuing education Resources For dog owners Clinical trials Blog Products Discover our longevity drugs and the principles guiding their development. Overview for vets Clinical resources, education, and insights on aging and treatments. Continuing education Stay current with the latest science on canine aging and longevity medicine. Resources for vets Access tools, data, and guidance to support clinical decisio … have completed the technical effectiveness portion of our conditional approval application for LOY-001’s use in large dog lifespan extension. As there was no established regulatory path for a lifespan extension drug, we had to design from scratch a scientifically strong and logistically feasible way to demonstrate efficacy of an aging drug. This process took more than four years, resulting in the 2,300+ page technical section now approved by the FDA. It included intervention
Loyal's second FDA acceptance for a drug to extend lifespan in senior dogs. | Josh Kopelman posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to … oved aging dog dying or having to put down. The goal of longevity studies is to apply it to humans, but every pet owner would be delighted to extend their dog’s lifespan. Dogs are a good model for this since their lifespan is relatively short (as a model organism) and their metabolism is well known. It is also well established that caloric restriction can extend lifespan. In the last few years, a biotechnology company called Loyal has been testing a medication that would mimi
Loyal Animal Health, Inc. Company Profile: Financials, Valuation, and Growth | PrivCo Sign In Create Free Account PrivCo Loyal Animal Health, Inc. Loyal Animal Health, Inc. San Francisco, California Watchlist Export About Financials People Deals Funding News About Loyal Animal Health, Inc. Company overview Loyal Animal Health, Inc. is a privately-held biotech firm that develops veterinary drug that delays the onset of age-related diseases like cancer, heart diseases, and metabolic diseases. Loyal Animal Health, Inc. was founded in 2019 by Celine Halioua. Loyal Animal Health, Inc. headquarters
we've renamed loyal's corporate entity from cellular longevity, inc to loyal animal health, inc.! this is so all of our regulatory docs are clearly + obviously tied to Loyal but don't worry, CL… | Celine Halioua LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your ch
Loyal’s Series C: $100M to advance the first longevity drug Skip to main content Products For vets Overview Continuing education Resources For dog owners Clinical trials Blog Products Discover our longevity drugs and the principles guiding their development. Overview for vets Clinical resources, education, and insights on aging and treatments. Continuing education Stay current with the latest science on canine aging and longevity medicine. Resources for vets Access tools, data, and guidance to support clinical decision-making. For dog owners Learn about aging, safety, and how to care for dogs … our team, and preparation for commercial launch. This round was led by age1, a fund backing breakthrough longevity companies, and the next generation of Laura Deming’s The Longevity Fund, where I started my career almost nine years ago. They were joined by Baillie Gifford and existing investors. Their support reflects growing conviction in the idea that aging is a biological process that can be measured, studied, and treated — and that veterinary medicine can lead the way. T
Loyal | First Round Take a tour of Notion's SF headquarters in our new series, "In Office" Watch Home Companies How we work Team Who we back PMF Method The Review Loyal Imagine if we had more time with the dogs we love. Loyal is a clinical-stage animal health company developing longevity drugs for dogs. By targeting the underlying mechanisms of aging, Loyal hopes to extend the lifespan of dogs and improve their quality of life as they age. As a solo-founder, Celine has put an outlier level of grit and effort into willing this deep tech company into existence. With over $150M rai
Founder and CEO, Loyal | Aspen Ideas Primary navigation Festival Attend the Aspen Ideas Festival June 25 - July 1, 2026 Event Overview The most engaged and curious people, all gathered in a single awe-inspiring place 2026 Festival Agenda Get ready for bold conversations, big ideas, and inspiring insights! 2026 Festival Speakers Inspiring leaders, brilliant thinkers, and curious seekers 2026 Festival Program Tracks Explore the forces shaping our world today Newsletter Subscribe for Festival updates, podcasts, articles, and more Health Attend Aspen Ideas: Health June 22-25, 2026 Event Overview W … ntative medicine. Celine then left Oxford to join Laura Deming at The Longevity Fund, one of the pioneering early investors in the longevity field. Celine has a B.S.A. in Neuroscience from the University of Texas. Previous Previously 2024 Festival New Leash on Life: Is Dog Longevity the Key to Ours? Scientists are developing life-extending drugs for dogs, and new advancements could bring them to market by 2025. Two leaders working to slow the aging process for Fido discus... … letter Sign up to receive the latest news from Aspen Ideas. Sign Up Here Search Submit Register Festival Health More Events Library About Attend the Aspen Ideas Festival Event Overview 2026 Festival Agenda 2026 Festival Speakers 2026 Festival Program Tracks Newsletter Attend Aspen Ideas: Health Event Overview 2026 Health Agenda 2026 Health Speaker Lineup 2026 Health Program Tracks Subscribe for Updates Aspen Ideas: Climate Aspen Ideas: Economy Explore All Sessions Podcasts Ar
About — Celine Halioua Celine Halioua How to Build a Biotech Writings Thoughts Memories & Art About How to Build a Biotech Writings Thoughts Memories & Art About Celine Halioua Hi, I’m Celine. I am the founder and CEO of Loyal , a biotech startup developing drugs to extend dog lifespan. I also dabble in biotech & deep-tech investing. Before that, I was a D.Phil. student at Oxford studying the health economics of gene therapy (St Peter’s College) & Chief of Staff to Laura Deming at Longevity Fund . I studied neuroscience and nanobiotechnology&nb … ogical aging. I am also interested in healthcare systems, specifically the application of socialized healthcare practices to the United States and the economic incentivization of preventative and curative medicine. I go by Celine Halioua, although in reality I actually have six names. All hyphenated. My mom is from Rabat, Morocco, my father from Berlin, Germany, and I was born in Austin, Texas. I have studied in Texas, Sweden, Germany, and England. I am not yet sur
Two Loyal-nominated compounds selected for the National Institute on Aging Interventions Testing Program Skip to main content Products For vets Overview Continuing education Resources For dog owners Clinical trials Blog Products Discover our longevity drugs and the principles guiding their development. Overview for vets Clinical resources, education, and insights on aging and treatments. Continuing education Stay current with the latest science on canine aging and longevity medicine. Resources for vets Access tools, data, and guidance to support clinical decision-making. For dog owners Learn a
Loyal | Blog Skip to main content One step closer to a longevity drug: LOY-002 hits key FDA milestone. Read more → Products For vets Overview Continuing education Resources For dog owners Clinical trials Blog Products Discover our longevity drugs and the principles guiding their development. Overview for vets Clinical resources, education, and insights on aging and treatments. Continuing education Stay current with the latest science on canine aging and longevity medicine. Resources for vets Access tools, data, and guidance to support clinical decision-making. For dog owners Learn about aging,
Loyal’s latest milestone: the first longevity clinical study design supported by the FDA Skip to main content Products For vets Overview Continuing education Resources For dog owners Clinical trials Blog Products Discover our longevity drugs and the principles guiding their development. Overview for vets Clinical resources, education, and insights on aging and treatments. Continuing education Stay current with the latest science on canine aging and longevity medicine. Resources for vets Access tools, data, and guidance to support clinical decision-making. For dog owners Learn about aging, safe
Loyal | About us Skip to main content One step closer to a longevity drug: LOY-002 hits key FDA milestone. Read more → Products For vets Overview Continuing education Resources For dog owners Clinical trials Blog Products Discover our longevity drugs and the principles guiding their development. Overview for vets Clinical resources, education, and insights on aging and treatments. Continuing education Stay current with the latest science on canine aging and longevity medicine. Resources for vets Access tools, data, and guidance to support clinical decision-making. For dog owners Learn about ag … ctor Partner, Bain Capital Ventures Laura Deming Director Founder/GP, Longevity Fund Blake Scholl Director Founder/CEO, Boom Supersonic Linda Rhodes, VMD, PhD Director Former CEO & Chief Scientific Officer, Aratana Therapeutics Stephen Betz, PhD Board Observer Founder/CSO, Crinetics Pharmaceuticals ($CRNX) Josh Kopelman Board Observer Founder/GP, First Round Capital Greg Rosen Board Observer Partner, Box Group Jonathan Shulkin Board Observer Partner/Co-President, Valor Eq
Biotech Company Loyal Appoints Blake Scholl to Board of Directors Please ensure Javascript is enabled for purposes of website accessibility Skip to content --> Select Region or Brand Business National Charleston, SC Columbia, SC Idaho Lehigh Valley Long Island Maryland Massachusetts Mecklenburg, NC Michigan Minnesota Missouri New Jersey New Orleans, LA New York North Carolina Oklahoma City, OK Oregon Pennsylvania Rhode Island Rochester Virginia Wisconsin Legal Maryland Massachussetts Michigan Minnesota Missouri New York North Carolina South Carolina Wisconsin Rhode Island Virginia Construction … ima Labs. Blake joins existing board of directors Laura Deming of The Longevity Fund and Celine Halioua, and board observers Josh Kopelman of First Round Capital and Greg Rosen of Box Group. “I’m extremely excited that Blake is joining Loyal’s Board. Blake is fascinated with longevity science, has a strong passion for tackling big, important problems, and has invaluable experience bringing entirely new products to consumers,” stated Loyal CEO and founder Celine Halioua. “I lo
Blake Scholl joins the Loyal Board of Directors Skip to main content Products For vets Overview Continuing education Resources For dog owners Clinical trials Blog Products Discover our longevity drugs and the principles guiding their development. Overview for vets Clinical resources, education, and insights on aging and treatments. Continuing education Stay current with the latest science on canine aging and longevity medicine. Resources for vets Access tools, data, and guidance to support clinical decision-making. For dog owners Learn about aging, safety, and how to care for dogs as they grow